Lasa Supergenerics Limited Cash Flow Conversion Efficiency
Lasa Supergenerics Limited cash flow conversion efficiency. Based on the latest financial reports, Lasa Supergenerics Limited (LASA) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.59 Million ≈ $27.98K USD) by net assets (Rs563.42 Million ≈ $6.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lasa Supergenerics Limited (2017–2025)
Cash flow conversion efficiency of Lasa Supergenerics Limited from 2017 to 2025. This chart illustrates how Lasa Supergenerics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LASA share price today for real-time trading data and today's change.
Lasa Supergenerics Limited Cash Flow Conversion Ratio Explained
Lasa Supergenerics Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lasa Supergenerics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lasa Supergenerics Limited ranked by their cash flow conversion efficiency. Also see Lasa Supergenerics Limited (LASA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lithium Energi Exploration Inc
V:LEXI
|
-1.507x |
|
Dongwon Systems Corp
KO:014825
|
0.072x |
|
Neurizer Ltd
AU:NRZ
|
-0.015x |
|
Preecha Group Public Company Limited
BK:PRECHA
|
-0.044x |
|
DecideAct A/S
CO:ACT
|
-1.946x |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
0.428x |
|
Dongbu Corp
KO:005965
|
0.058x |
|
Mobi724 Global Solutions Inc
V:MOS
|
0.023x |
Annual Cash Flow Conversion Efficiency for Lasa Supergenerics Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Lasa Supergenerics Limited from 2017 to 2025. Review Lasa Supergenerics Limited free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs837.13 Million ≈ $9.05 Million |
Rs-28.24 Million ≈ $-305.37K |
-0.034x | -252.47% |
| 2024-03-31 | Rs966.76 Million ≈ $10.46 Million |
Rs21.39 Million ≈ $231.29K |
0.022x | +115.13% |
| 2023-03-31 | Rs1.18 Billion ≈ $12.79 Million |
Rs-173.00 Million ≈ $-1.87 Million |
-0.146x | -350.68% |
| 2022-03-31 | Rs1.58 Billion ≈ $17.07 Million |
Rs92.12 Million ≈ $996.20K |
0.058x | -77.56% |
| 2021-03-31 | Rs1.59 Billion ≈ $17.19 Million |
Rs413.10 Million ≈ $4.47 Million |
0.260x | +169.95% |
| 2020-03-31 | Rs1.41 Billion ≈ $15.30 Million |
Rs136.23 Million ≈ $1.47 Million |
0.096x | -75.06% |
| 2019-03-31 | Rs1.05 Billion ≈ $11.39 Million |
Rs406.58 Million ≈ $4.40 Million |
0.386x | +12.48% |
| 2018-03-31 | Rs1.17 Billion ≈ $12.69 Million |
Rs402.80 Million ≈ $4.36 Million |
0.343x | +962.97% |
| 2017-03-31 | Rs754.94 Million ≈ $8.16 Million |
Rs-30.03 Million ≈ $-324.76K |
-0.040x | -- |
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more